(Q33409459)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23906020%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23906020%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23906020%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Anna Skowronska

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23906020%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

12 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23906020%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23906020%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23906020%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23906020%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

1227-1239

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23906020%20AND%20SRC:MED&resulttype=core&format=json

Chronic lymphocytic leukemia

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Clinical and diagnostic implications of monoclonal B-cell lymphocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Chronic lymphocytic leukemia: a tale of one or two signals?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Risk stratification in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

New prognostic markers in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Trisomy 12 CLLs progress through NOTCH1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Importance of genetics in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Interphase fluorescence in situ hybridization analysis of del(11)(q23) and del(17)(p13) in chronic lymphocytic leukemia. a study of 40 early-onset patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Clinical implications of the molecular genetics of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

21 January 2018

How I treat CLL up front

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

TP53 mutation and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Functional consequences of sequence alterations in the ATM gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Functional link between BLM defective in Bloom's syndrome and the ataxia-telangiectasia-mutated protein, ATM

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

DNA damage-induced association of ATM with its target proteins requires a protein interaction domain in the N terminus of ATM.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Identification of domains of ataxia-telangiectasia mutated required for nuclear localization and chromatin association.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

A novel Tel1/ATM N-terminal motif, TAN, is essential for telomere length maintenance and a DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

ATM's leucine-rich domain and adjacent sequences are essential for ATM to regulate the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

The Mre11/Rad50/Nbs1 complex and its role as a DNA double-strand break sensor for ATM.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Autophosphorylation and ATM activation: additional sites add to the complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Characteristics of gamma-H2AX foci at DNA double-strand breaks sites

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Enhanced phosphorylation of p53 by ATM in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Chk2 activation dependence on Nbs1 after DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Structural biochemistry and interaction architecture of the DNA double-strand break repair Mre11 nuclease and Rad50-ATPase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Mre11 Dimers Coordinate DNA End Bridging and Nuclease Processing in Double-Strand-Break Repair

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Ataxia-telangiectasia-mutated dependent phosphorylation of Artemis in response to DNA damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Interaction between ATM protein and c-Abl in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients, with 5762ins137 and 7271T-->G mutations, showing a less severe phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

CtIP links DNA double-strand break sensing to resection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

The switch from survival responses to apoptosis after chromosomal breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Regulation of cell death by the Abl tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

ATM-dependent nuclear accumulation of IKK-alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

E2F1 transcription is induced by genotoxic stress through ATM/ATR activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

ATM activation by oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

ATM/ATR checkpoint activation downregulates CDC25C to prevent mitotic entry with uncapped telomeres

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

ATM stabilizes DNA double-strand-break complexes during V(D)J recombination.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

ATM is required for efficient recombination between immunoglobulin switch regions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Disparate roles of ATR and ATM in immunoglobulin class switch recombination and somatic hypermutation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Breast and other cancers in families with ataxia-telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

ATM mutations are rare in familial chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

FAT: a novel domain in PIK-related kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

Electron microscopy and 3D reconstructions reveal that human ATM kinase uses an arm-like domain to clamp around double-stranded DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.829919

10.3109/10428194.2013.829919

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23906020%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference